# FACTORS CONTRIBUTING TO THE SUCCESS OF ACINETOBACTER BAUMANNII AS A HUMAN PATHOGEN

# BY BART A. EIJKELKAMP

A thesis submitted for the Degree of Doctor of Philosophy

The School of Biological Sciences Flinders University

October 2011

### TABLE OF CONTENTS

TABLE OF FIGURES	VII
DATA TABLES	IX
ABSTRACT	X
DECLARATION	
ACKNOWLEDGEMENTS	
CONTRIBUTIONS	
PUBLICATIONS	
	2 <b>x v</b>
CHAPTER 1 GENERAL INTRODUCTION	1
1.1 A. baumannii; a significant human pathogen with an alarming potential	2
1.1.1 Acinetobacter classification remains under debate	3
1.1.2 The global spread of successful A. baumannii clonal lineages	
1.1.3 A. baumannii can cause a wide range of infections	
1.1.4 Cost-related consequences in the clinical setting	
1.1.5 A. baumannii as a community-acquired pathogen	6
1.1.5.1 Carriage of Acinetobacter	6
1.1.5.2 Prevalence of community-acquired A. baumannii is higher in	
(sub)tropical areas	6
1.1.5.3 Post-traumatic community-acquired A. baumannii infections	
1.2 Mechanisms involved in <i>A. baumannii</i> virulence and persistence	7
1.2.1 Iron acquisition mechanisms	8
1.2.1.1 The importance of iron acquisition for pathogens	
1.2.1.2 Siderophore-mediated iron acquisition	
1.2.1.3 Iron acquisition in <i>A. baumannii</i>	
1.2.2 Adherence to abiotic surfaces and biofilm formation	
1.2.2.1 Persistence of <i>A. baumannii</i> in the hospital environment	0
1.2.2.2 Various mechanisms contribute to abiotic surface adherence	9
and biofilm formation	11
1.2.3 The interaction between <i>A. baumannii</i> and eukaryotic cells	
1.2.4 Acinetobacter motility characteristics	
1.2.4.1 The different forms of bacterial motility	
1.2.4.2 The role of motility in virulence	
1.2.4.3 Motility of <i>Acinetobacter</i> species	15
1.3. A haumannii contains a broad arsenal of resistance mechanisms	16

	1.3.1	Antibiotic modifying enzymes	
	1.3.2	Resistance as a result of genetic mutations	17
	1.3.3	Resistance due to loss of porin proteins	17
	1.3.4	Efflux-mediated resistance	18
	1.3.4.	The ATP-binding cassette superfamily	20
	1.3.4.2		
	1.3.4.		
	1.3.4.4	-	
	1.3.4.		
	1.3.5	The need for development of novel antimicrobial therapies	24
	1.3.5.	1 'Last resort' antibiotics	25
	1.3.5.2	2 Combination therapies	26
	1.3.5.		
	1.3.5.4		
1 4	What has	ve genomic analyses taught us so far?	
1.7			
		AbaR-type resistance islands	
		A. baumannii plasmids are highly variable between strains	31
		The role of insertion sequences in shaping the A. baumannii	21
		genome	31
1.5	Scope of	this thesis	32
СП	ADTED 1	MATERIALS AND METHODS	21
		2 MATERIALS AND METHODS	
		nd growth media	
	Buffers a		35
	Buffers a	nd growth media	35
2.1	Buffers a 2.1.1 2.1.2	nd growth mediaSolutions and buffersBacterial culture media	35 35
2.1	Buffers a 2.1.1 2.1.2 Bacterial	nd growth mediaSolutions and buffers	35 35 35
2.1	Buffers a 2.1.1 2.1.2 Bacterial Bacterial	nd growth media  Solutions and buffers  Bacterial culture media  strains and growth conditions characterisation assays	35 35 35 35
2.1	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1	nd growth media  Solutions and buffers  Bacterial culture media  strains and growth conditions  characterisation assays  International clone determination	35 35 35 45
2.1	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2	nd growth media  Solutions and buffers  Bacterial culture media  strains and growth conditions characterisation assays  International clone determination  Minimal inhibitory concentration assays	35 35 35 45 45
2.1	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3	nd growth media  Solutions and buffers  Bacterial culture media  strains and growth conditions characterisation assays  International clone determination  Minimal inhibitory concentration assays  Static biofilm formation assays	35 35 35 45 45 45
2.1	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3 2.3.4	nd growth media  Solutions and buffers  Bacterial culture media  strains and growth conditions characterisation assays  International clone determination  Minimal inhibitory concentration assays  Static biofilm formation assays  Motility assays	35 35 35 45 45 45
2.1	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3 2.3.4 2.3.5	nd growth media  Solutions and buffers  Bacterial culture media  strains and growth conditions characterisation assays  International clone determination  Minimal inhibitory concentration assays  Static biofilm formation assays  Motility assays  Pellicle formation assays	35 35 35 45 45 46 46
2.1	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3 2.3.4 2.3.5 2.3.6	nd growth media  Solutions and buffers  Bacterial culture media  strains and growth conditions characterisation assays  International clone determination  Minimal inhibitory concentration assays  Static biofilm formation assays  Motility assays  Pellicle formation assays  Eukaryotic cell adherence assays	3535354545464647
2.1	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3 2.3.4 2.3.5 2.3.6 2.3.7	nd growth media  Solutions and buffers  Bacterial culture media  strains and growth conditions characterisation assays  International clone determination  Minimal inhibitory concentration assays  Static biofilm formation assays  Motility assays  Pellicle formation assays  Eukaryotic cell adherence assays  Hydrophobicity test	35 35 35 45 45 46 46 46 47
2.1	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3 2.3.4 2.3.5 2.3.6 2.3.7 2.3.8	nd growth media  Solutions and buffers  Bacterial culture media  strains and growth conditions characterisation assays  International clone determination  Minimal inhibitory concentration assays  Static biofilm formation assays  Motility assays  Pellicle formation assays  Eukaryotic cell adherence assays  Hydrophobicity test  Phenotype MicroArray analysis	35353545454646474748
2.1 2.2 2.3	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3 2.3.4 2.3.5 2.3.6 2.3.7 2.3.8 2.3.9	nd growth media  Solutions and buffers  Bacterial culture media  strains and growth conditions characterisation assays  International clone determination  Minimal inhibitory concentration assays  Static biofilm formation assays  Motility assays  Pellicle formation assays  Eukaryotic cell adherence assays  Hydrophobicity test  Phenotype MicroArray analysis  Statistical analyses	35353545454646474748
2.1 2.2 2.3	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3 2.3.4 2.3.5 2.3.6 2.3.7 2.3.8 2.3.9 DNA and	nd growth media	35353545454646474848
2.1 2.2 2.3	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3 2.3.4 2.3.5 2.3.6 2.3.7 2.3.8 2.3.9 DNA and 2.4.1	nd growth media	3535354545464647474848
2.1 2.2 2.3	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3 2.3.4 2.3.5 2.3.6 2.3.7 2.3.8 2.3.9 DNA and 2.4.1 2.4.2	Solutions and buffers Bacterial culture media strains and growth conditions characterisation assays International clone determination Minimal inhibitory concentration assays Static biofilm formation assays Motility assays Pellicle formation assays Eukaryotic cell adherence assays Hydrophobicity test Phenotype MicroArray analysis Statistical analyses I RNA techniques Plasmid DNA isolation Genomic DNA isolation	353535454546464748484848
2.1 2.2 2.3	Buffers a 2.1.1 2.1.2 Bacterial Bacterial 2.3.1 2.3.2 2.3.3 2.3.4 2.3.5 2.3.6 2.3.7 2.3.8 2.3.9 DNA and 2.4.1 2.4.2 2.4.3	nd growth media	35353545454646474848484849

	2.4.5	Purification of DNA fragments	50
	2.4.6	Quantitation and quality assessment	50
	2.4.7	DNA sequencing	50
	2.4.8	Conventional cloning	50
	2.4.9	Gateway cloning.	51
	2.4.10	Preparation of chemically competent <i>E. coli</i> cells	51
	2.4.11	Transformation of chemically competent E. coli cells	51
	2.4.12	Preparation of electrocompetent A. baumannii cells	52
	2.4.13	Transformation of electrocompetent A. baumannii cells	52
	2.4.14	Polymerase chain reaction.	52
	2.4.15	Quantitative reverse transcription-PCR	60
2.5	Microar	ray analyses	60
	2.5.1	Array development	60
	2.5.2	cDNA synthesis and microarray hybridisation	60
2.6	Protein	detection	61
	2.6.1	Sample preparation	61
	2.6.2	DC-BCA protein assay	61
	2.6.3	SDS-PAGE	62
	2.6.4	Coomassie stain	62
	2.6.5	Protein transfer to polyvinylidine fluoride membrane	62
	2.6.6	Immunological detection of recombinant proteins	62
2.7	Bioinfor	matic analyses	63
	2.7.1	Alignments and in silico manipulations	63
	2.7.2	Genomic DNA analyses	
	2.7.3	Motif and DNA binding site analyses	64
СН	APTER	3 INVESTIGATION OF THE HUMAN PATHOGEN  ACINETOBACTER BAUMANNII UNDER IRON- LIMITING CONDITIONS	65
3.1	Introduc	etion	66
3.2	Results	and Discussion	67
	3.2.1	Optimisation of test conditions for transcriptomic analysis	67
	3.2.2	Global transcriptional changes of A. baumannii ATCC 17978 to	
	222	iron starvation.	
	3.2.3 3.2.4	A. baumannii FUR box optimisation	/ 3
	3.2.4	Transcriptional profiling of the siderophore-mediated iron acquisition mechanisms	77
	3.2.5	Investigation of motility under iron-limiting conditions	
	3.2.5	Comparative analysis of the iron acquisition mechanisms of	60
	3.2.0	sequenced <i>Acinetobacter</i> isolates	Q/I
	3.2.7	A second FUR-like transcription repressor	
2.2		• •	
3.3	Conclus	ions	91

CHAPTER 4 ADHERENCE AND MOTILITY CHARACTERISTICS OF CLINICAL ACINETOBACTER BAUMANNII	
ISOLATES	93
4.1 Introduction	94
4.2 Results and Discussion	95
4.2.1 Strain selection and clonality	95
4.2.2 Motility of A. baumannii	
4.2.3 Adherence to abiotic surfaces and biofilm formation	
4.2.4 Adherence to eukaryotic cell surfaces	99
4.2.5 Genomic analysis of <i>A. baumannii</i> motility and adherence features	99
4.3 Conclusions	
CHAPTER 5 PHENOTYPIC AND MOLECULAR EXAMINATION OF A HYPER-MOTILE ACINETOBACTER BAUMANNII VARIANT STRAIN	107
5.1 Introduction	
5.2 Results and Discussion	
5.2.1 Isolation of <i>A. baumannii</i> 17978hm; a hyper-motile variant strain	109
5.2.1.1 Motility characteristics	
5.2.2 Adherence characteristics	114
5.2.2.1 Adherence to abiotic surfaces and biofilm formation	114
5.2.2.2 Pellicle formation	
5.2.2.3 Adherence to eukaryotic cells	115
<ul><li>5.2.3 Cell surface hydrophobicity</li><li>5.2.4 Transcriptomic analysis of the motile versus non-motile</li></ul>	
population	
5.2.4.1 Design of the study	
motile cells	121
5.2.5 Examination of metabolic differences	124
5.2.5.1 Expression levels of <i>paaA</i>	
5.2.6 Signal transduction in <i>A. baumannii</i>	
5.2.6.1 The genomic organisation of the region harbouring the	
quorum-sensing signal biosynthesis cluster	129
5.2.6.2 Investigation of AbaR binding sites	131

	5.2.6	3 Lon protease	132
	5.2.7	Genome sequence analysis of <i>A. baumannii</i> strains ATCC 17978 and 17978hm	133
	5.2.7 5.2.7		133
	5.2.7	like protein	
	5.2.8	The effect of stress on motility and adherence	142
	5.2.8 5.2.8 5.2.8 5.2.8	2 Inhibition of motility as a result of environmental stress	144 148
	5.2.9	Transcriptional profiling of A. baumannii under stress conditions	152
	5.2.9 5.2.9		152
	5.2.9		
		regulated in a saline environmentions	
		CLONING STRATEGY FOR CHARACTERISATION OF	
		ACINETOBACTER BAUMANNII DRUG TRANSPORTER	159
6.1	Introduc	ACINETOBACTER BAUMANNII DRUG TRANSPORTER PROTEINS	
		ACINETOBACTER BAUMANNII DRUG TRANSPORTER	160
		ACINETOBACTER BAUMANNII DRUG TRANSPORTER PROTEINS	160 161
	Results	ACINETOBACTER BAUMANNII DRUG TRANSPORTER PROTEINS	160 161 161 165
	6.2.1 6.2.2 6.2.3 6.2.4	ACINETOBACTER BAUMANNII DRUG TRANSPORTER PROTEINS  etion  and Discussion  The prevalence of drug transporters in clinical A. baumannii isolates  Annotation and isolation of the A. baumannii efflux systems  Construction of a Gateway-based cloning system for heterologous expression of membrane proteins  Functional characterisation of A. baumannii efflux systems	160 161 161 165 166
6.2	6.2.1 6.2.2 6.2.3 6.2.4 6.2.5	ACINETOBACTER BAUMANNII DRUG TRANSPORTER PROTEINS  etion  and Discussion  The prevalence of drug transporters in clinical A. baumannii isolates  Annotation and isolation of the A. baumannii efflux systems  Construction of a Gateway-based cloning system for heterologous expression of membrane proteins  Functional characterisation of A. baumannii efflux systems  Constructing directed A. baumannii knockout strains	161 161 165 166 169 172
6.2	6.2.1 6.2.2 6.2.3 6.2.4 6.2.5	ACINETOBACTER BAUMANNII DRUG TRANSPORTER PROTEINS  etion  and Discussion  The prevalence of drug transporters in clinical A. baumannii isolates  Annotation and isolation of the A. baumannii efflux systems  Construction of a Gateway-based cloning system for heterologous expression of membrane proteins  Functional characterisation of A. baumannii efflux systems	161 161 165 166 169 172
6.2	6.2.1 6.2.2 6.2.3 6.2.4 6.2.5 Conclus	ACINETOBACTER BAUMANNII DRUG TRANSPORTER PROTEINS  etion  and Discussion  The prevalence of drug transporters in clinical A. baumannii isolates  Annotation and isolation of the A. baumannii efflux systems  Construction of a Gateway-based cloning system for heterologous expression of membrane proteins  Functional characterisation of A. baumannii efflux systems  Constructing directed A. baumannii knockout strains	161 161 165 166 169 172
6.2 6.3 <b>CH</b>	6.2.1 6.2.2 6.2.3 6.2.4 6.2.5 Conclus	ACINETOBACTER BAUMANNII DRUG TRANSPORTER PROTEINS  tion and Discussion  The prevalence of drug transporters in clinical A. baumannii isolates.  Annotation and isolation of the A. baumannii efflux systems  Construction of a Gateway-based cloning system for heterologous expression of membrane proteins.  Functional characterisation of A. baumannii efflux systems  Constructing directed A. baumannii knockout strains	160 161 165 166 169 172 176
6.2 6.3 <b>CH</b>	6.2.1 6.2.2 6.2.3 6.2.4 6.2.5 Conclus  IAPTER  A. baum 7.1.1	ACINETOBACTER BAUMANNII DRUG TRANSPORTER PROTEINS  tion and Discussion  The prevalence of drug transporters in clinical A. baumannii isolates.  Annotation and isolation of the A. baumannii efflux systems  Construction of a Gateway-based cloning system for heterologous expression of membrane proteins  Functional characterisation of A. baumannii efflux systems  Constructing directed A. baumannii knockout strains  ions  7 CONCLUSIONS AND DISCUSSION  annii persistence mechanisms  Biofilm formation	160 161 165 166 169 172 176 178 179
6.2 6.3 <b>CH</b>	6.2.1 6.2.2 6.2.3 6.2.4 6.2.5 Conclus IAPTER A. baum	ACINETOBACTER BAUMANNII DRUG TRANSPORTER PROTEINS  tion and Discussion  The prevalence of drug transporters in clinical A. baumannii isolates  Annotation and isolation of the A. baumannii efflux systems  Construction of a Gateway-based cloning system for heterologous expression of membrane proteins  Functional characterisation of A. baumannii efflux systems  Constructing directed A. baumannii knockout strains  ions  7 CONCLUSIONS AND DISCUSSION  annii persistence mechanisms	160 161 165 166 169 172 176 178 178

7.2	The med	chanisms involved in A. baumannii motility	182
	7.2.1	Pili-mediated motility	182
	7.2.2	Hydrophobicity and biosurfactant production	183
	7.2.3	Distinct A. baumannii strains employ different mechanisms for	
		motility	185
7.3	Regulate	ory mechanisms involved in A. baumannii persistence	187
	7.3.1	Quorum-sensing is essential for A. baumannii motility	187
	7.3.2	The involvement of H-NS in expression of the A. baumannii	
		persistence features	188
7.4	The imp	ortance of iron acquisition in A. baumannii	190
		nediated resistance	
		analyses	
		ions	
СН	APTER	8 APPENDICES	196
App	endix A	Genes significantly up-regulated in A. baumannii strain ATCC	
		17978 under iron-limiting conditions	197
App	endix B	Genes significantly down-regulated in A. baumannii strain	
		ATCC 17978 under iron-limiting conditions	209
App	endix C	ATCC 17978 FUR binding sites	227
App	endix D	Genes more than 2-fold up-regulated in A. baumannii strain	
		17978hm compared to strain ATCC 17978	230
App	endix E	Genes more than 2-fold down-regulated in A. baumannii strain	
		17978hm compared to strain ATCC 17978	236
App	endix F	Eijkelkamp et al. 2011; BMC Genomics	246
App	endix G	Eijkelkamp et al. 2011; FEMS Microbiology Letters	260
App	endix H	Eijkelkamp et al. 2011; Journal of Molecular Microbiology and	
		Biotechnology	268
App	endix I	Abbreviations	277
CII	A DOTED	0 DEFEDENCES	200

# **TABLE OF FIGURES**

Figure 1.1:	The five families of drug transporters	. 19
Figure 1.2:	Genomic comparison of the A. baumannii AbaR resistance islands	. 30
Figure 3.1:	Growth curves of <i>A. baumannii</i> strain ATCC 17978 with varying iron concentrations	. 68
Figure 3.2:	Overview of transcriptional responses of <i>A. baumannii</i> strain ATCC 17978 to iron starvation	. 70
Figure 3.3:	Microarray results of <i>A. baumannii</i> strain ATCC 17978 under iron-limiting and iron-replete conditions displayed by COG function	.72
Figure 3.4:	The optimised A. baumannii ATCC 17978 FUR motif	.76
Figure 3.5:	Transcriptional profiling of three siderophore gene clusters identified in <i>A. baumannii</i> strain ATCC 17978	.78
Figure 3.6:	A. baumannii ATCC 17978 gene clusters with a putative role in motility	. 83
Figure 3.7:	Swarming motility of A. baumannii strain ATCC 17978	. 85
Figure 3.8:	Comparison of siderophore cluster 1 between <i>A. baumannii</i> ATCC 17978 and SDF	. 88
Figure 4.1:	Characterisation of Acinetobacter isolates	.97
Figure 4.2:	Adherence of A. baumannii strains to eukaryotic epithelial cells	100
Figure 4.3:	PilA similarity analysis	102
Figure 5.1:	Identification of the hyper-motile variant strain	110
Figure 5.2:	Growth curves of <i>A. baumannii</i> ATCC 17978 and the hyper-motile variant	111
Figure 5.3:	Analysis of the protein content of <i>A. baumannii</i> strain ATCC 17978 and the hyper-motile variant	113
Figure 5.4:	Pellicle formation by <i>A. baumannii</i> strains ATCC 17978 and 17978hm	116
Figure 5.5:	Adherence to A549 human lung epithelial cells	118
Figure 5.6:	Cell surface hydrophobicity	119
Figure 5.7:	Overview of transcriptional differences between motile and non-motile <i>A. baumannii</i> cells	122
Figure 5.8:	Transcriptomic data of motile versus non-motile <i>A. baumannii</i> cells represented by COG function	123
Figure 5.9:	Comparative analysis of carbon source utilisation	127

Figure 5.10:	Genetic organisation of A. baumannii QS-regulated genes	130
Figure 5.11:	Positioning of the insertion elements identified in A1S_0268 of <i>A. baumannii</i> strains 17978hm and B23	137
Figure 5.12:	Comparative analysis of the transcriptome results and genomic conservation	141
Figure 5.13:	Motility phenotypes of $A.\ baumannii$ strain 17978hm under stress	146
Figure 5.14:	Biofilm formation under stress conditions	149
Figure 5.15:	Pellicle formation of <i>A. baumannii</i> strain 17978hm under stress conditions	151
Figure 6.1:	The Gateway-based expression systems used for expression of <i>A. baumannii</i> efflux proteins	168
Figure 6.2:	Western blot detection of heterologously expressed <i>A. baumannii</i> efflux proteins in <i>E. coli</i>	170
Figure 6.3:	The <i>A. baumannii</i> insertion disruption strategy developed in this study	174

# **DATA TABLES**

Table 2.1:	Buffers and solutions	36
Table 2.2:	Bacterial strains used in this study	37
Table 2.3:	Plasmids used in this study	41
Table 2.4:	Oligonucleotides used in this study	53
Table 3.1:	Validation of the transcriptomic data by comparison of expression levels determined by microarray and qRT-PCR analysis	71
Table 3.2:	Putative FUR binding sequences in the <i>A. baumannii</i> ATCC 17978 genome used for generating the FUR box motif	75
Table 3.3:	Characteristics of the putative <i>A. baumannii</i> ATCC 17978 siderophore receptors	81
Table 3.4:	Genomic comparison of siderophore gene clusters in sequenced Acinetobacter isolates	87
Table 3.5:	The ability of different <i>Acinetobacter</i> strains to grow under iron-limiting conditions	90
Table 4.1:	Presence of type I pili cluster in fully sequenced <i>A. baumannii</i> isolates	. 103
Table 5.1:	Single nucleotide polymorphisms identified in the <i>A. baumannii</i> 17978hm genome	. 135
Table 5.2:	Signal strengths of A1S_0268 and A1S_0628 in <i>A. baumannii</i> strains ATCC 17978 and 17978hm determined by microarray	. 139
Table 5.3:	Complementation of the <i>A. baumannii</i> ATCC 17978 A1S_0268 mutant strains	. 143
Table 5.4:	Antimicrobial MIC values of <i>A. baumannii</i> strain ATCC 17978 and 17978hm	. 145
Table 5.5:	Motility of A. baumannii strain 17978hm under stress	. 147
Table 5.6:	Transcriptional responses of <i>A. baumannii</i> strain 17978hm under different stress conditions	. 154
Table 6.1:	Characteristics and prevalence of the <i>A. baumannii</i> ATCC 17978 drug transporters	. 162
Table 6.2:	Substrate profile of heterologously expressed <i>A. baumannii</i> efflux proteins in <i>E. coli</i>	. 171

#### **ABSTRACT**

Acinetobacter baumannii is a major problem in the hospital setting and also shows significance as a community-acquired pathogen in tropical climates, including parts of Australia. The increase in resistance to widely used antibiotics is evident and signs of pan-resistance are emerging. Epidemiological studies have shown global dissemination of successful clones, explaining the occurrence of troublesome A. baumannii outbreaks worldwide. However, the wide variety of A. baumannii resistance and persistence mechanisms remains poorly understood. This can be partially attributed to the phenotypic and genetic variation observed between clinical A. baumannii strains.

Iron acquisition systems are important virulence factors in pathogenic bacteria. To identify these systems in *A. baumannii*, the transcriptomic response of the fully sequenced strain ATCC 17978 under iron-limiting conditions was investigated. Of particular significance, three siderophore biosynthesis gene clusters, including one novel cluster, were highly up-regulated. Various genes involved in motility featured prominently amongst the genes down-regulated when iron was less readily available. Motility assays confirmed that these transcriptional changes are manifested at the phenotypic level.

The clonal relationship, and the motility and adherence characteristics of 54 Australian clinical isolates and various fully sequenced *Acinetobacter* strains were investigated. The majority of the strains were classified as part of the international clone groups I and II, as seen in other parts of the world. However, unlike distribution of clinical *A. baumannii* isolates in Europe or the United States, international clone III isolates were not identified in our collection. Motility was found to be a common trait in *A. baumannii* international clone I strains and in abundant biofilm formers not part of the international clone I group. A high level of variability in adherence to both abiotic surfaces and human lung epithelial cells was found.

A derivative of strain *A. baumannii* ATCC 17978, isolated in this study, was found to possess enhanced motility and adherence characteristics. An insertion event of a mobile genetic element into a gene encoding a histone-like protein (A1S\_0268)

was identified by whole genome sequencing. Introduction of the wild-type A1S\_0268 gene in the variant strain using an *Acinetobacter/E. coli* shuttle vector complemented the altered motility and adherence characteristics, making it indistinguishable to the wild-type *A. baumannii* ATCC 17978 parent. Transcriptional profiling of the variant strain under motile conditions assisted in identification of molecular mechanisms that play a putative role in *A. baumannii* adherence and motility. Investigation of motility, adherence and transcription levels of various molecular mechanisms, including type IV pili, under different conditions, such as low iron and high salt, showed that *A. baumannii* is highly responsive to stress.

Active transport of antimicrobial agents mediated by efflux proteins contributes to the high level of multidrug resistance observed in *A. baumannii*. Novel multidrug efflux systems were identified using a number of Gateway-based destination vectors constructed in this study. Additionally, a Gateway-based suicide vector was designed for construction of specific *A. baumannii* insertion disruption mutants. This knockout strategy was shown to be successful in disrupting a novel drug transporter.

Examination of the extensive collection of *A. baumannii* isolates at a genetic, transcriptional, protein and cellular level assisted in delineating factors that contribute to the success of *A. baumannii* as a human pathogen. The importance of various molecular mechanisms in persistence, resistance and disease potential has been described in this thesis.

#### **DECLARATION**

I certify that this thesis does not incorporate without acknowledgment any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

Bart A. Eijkelkamp

#### **ACKNOWLEDGEMENTS**

I would first like to thank my supervisor Associate Professor Melissa Brown for giving me the opportunity to conduct my PhD project in her lab. Your support and advice throughout the last few years allowed me to get to this stage. There have been many people that have made working in the lab an enjoyable experience; Angela, Ming, Kim, Michael, Joanna, Sylvia, Eleni, Alisha, Mohsen, Charlotte, Sarah and Daniela, thanks guys, I could not have done it without you! A special thanks to Uwe, the lengthy discussions and casual chats were crucial for the project and for completing this thesis.

I would also like to acknowledge my co-supervisor Professor Ian Paulsen and the people in the Paulsen lab that I had the pleasure of working with; Sasha, Liam, Amanda, Kent, Ani and Dan, I am grateful for the numerous times you welcomed me in the lab in Sydney. Furthermore, I learned how to approach the project in a completely different way. Karl, I really enjoyed working with you and I will never forget your endless support. Even although it was on a distance, you have also become a real mate.

I am thankful to my friends on the third floor that introduced me to the great Australian lifestyle from the day I arrived; Nick, Emma, Pradeep, Simon, Bianca, Mel S, Patrick, Mel P, Ana, Drew, Peter, Chevaun and Lexi. The person that has kept me sane during my PhD is my girlfriend. Mel, you have always pushed me into having a life beside work. Being overseas for this long would not have been possible without you. Also, Ron and Jane thank you so much for everything!

Pa, ma en de rest van de familie, heel erg bedankt voor jullie steun, niet alleen voor de periode hier in Australië, maar voor de gehele studietijd. Ook wil ik mijn vrienden bedanken (met name Ruudje). Ookal is het lastig om over een grote aftstand over de frustraties en successen van een promotie onderzoek te praten, ik weet dat jullie altijd achter me stonden. Ik hoop dat we in de nabije toekomst dichter bij elkaar kunnen wonen om weer eens 'gewoon' een biertje te kunnen drinken.

#### **CONTRIBUTIONS**

Dr. KA Hassan (Macquarie University, Sydney, Australia) designed the microarray containing DNA probes to all predicted open reading frames of the A. baumannii ATCC 17978 genome and assisted with processing of the transcriptomic data. Furthermore, examination of carbon source utilisation by strains A. baumannii ATCC 17978 and a hyper-motile derivative of strain ATCC 17978, called A. baumannii 17978hm, were performed by Dr. KA Hassan using MicroPlate<sup>™</sup> PM1 and PM2A (BIOLOG). The DNA sequence reads obtained by whole genome shotgun analysis of A. baumannii strains WM99c, D1279779, ATCC 17978 and 17978hm were assembled by Dr. LDH Elbourne (Macquarie University, Sydney, Australia). Bioinformatic identification of genes encoding putative drug transporters in the A. baumannii ATCC 17978 genome was also performed by Dr. LDH Elbourne, using the transautomated annotation pipeline (TransAAP; www.membranetransport.org). Part of the international clone determination PCRs were performed by Mr. MS Papadimitrious (Flinders University, Adelaide, Australia). The eukaryotic cell binding assays were performed in parallel with Dr. UH Stroeher (Flinders University, Adelaide, Australia).

#### **PUBLICATIONS**

#### Published work arising from data compiled in this thesis

**Eijkelkamp BA, Hassan KA, Paulsen IT and Brown MH** (2011). Investigation of the human pathogen *Acinetobacter baumannii* under iron-limiting conditions. *BMC Genomics*, **12**:126. (Appendix F).

Eijkelkamp BA, Stroeher UH, Hassan KA, Papadimitrious MS, Paulsen IT and Brown MH (2011). Adherence and motility characteristics of clinical *Acinetobacter baumannii* isolates. *FEMS Microbiology Letters*, **323**:44-51. (Appendix G).

**Eijkelkamp BA, Hassan KA, Paulsen IT and Brown MH** (2011). Development of a high-throughput cloning strategy for characterisation of *Acinetobacter baumannii* drug transporter proteins. *Journal of Molecular Microbiology and Biotechnology*, **20**:211-219. (Appendix H).

**Eijkelkamp BA, Hassan KA, Paulsen IT and Brown MH**. Efflux systems of the nosocomial pathogens *Staphylococcus aureus* and *Acinetobacter baumannii*. *Microbial Efflux Pumps: Current Research*. Manuscript submitted.

Eijkelkamp BA, Stroeher UH, Hassan KA, Elbourne LDL, Paulsen IT and Brown MH. H-NS plays a role in expression of the *Acinetobacter baumannii* persistence and virulence features. Manuscript in preparation.

#### **Abstracts**

Hassan KA, <u>Penesyan A</u>, Li L, Varkey D, Farrugia D, Eijkelkamp BA, Brown MH and Paulsen IT Efflux mediated drug resistance in *Acinetobacter baumannii*. *ASM 2011*, Hotel Grand Chancellor, Hobart, Tasmania, Australia 4<sup>th</sup> – 8<sup>th</sup> July 2011.

<u>Hassan KA</u>, Brzoska AJ, Wilson NL, Varkey DR, Eijkelkamp BA, Brown MH and Paulsen IT Analysis of DHA2 family exporters in *Acinetobacter* spp. reveals putative functions in drug resistance and iron homeostasis, *Gordon Research Conferences on Multi-Drug Efflux Systems*, Les Diablerets Conference Center, Les Diablerets, Switzerland 12<sup>th</sup> – 17<sup>th</sup> July 2011.

**Eijkelkamp BA, Hassan KA, Paulsen IT and Brown MH** Investigation of the human pathogen *Acinetobacter baumannii* under iron-limiting conditions.  $8^{th}$  *International Symposium on the Biology of Acinetobacter*, University of Roma Tre, Roma, Italy  $1^{st} - 3^{rd}$  September 2010.

Eijkelkamp BA, Hassan KA, Paulsen IT and Brown MH Investigation of the human pathogen *Acinetobacter baumannii* under iron-limiting conditions. *ASM* 2010, Sydney Convention Centre, New South Wales, Australia 4<sup>th</sup> – 8<sup>th</sup> July 2010.

<u>Eijkelkamp BA</u>, Hassan KA, Papadimitrious MS, Cyza J, Paulsen IT and Brown MH Characterisation of the *Acinetobacter baumannii* efflux systems. *BacPath10*, Novotel Barossa Valley Resort, South Australia, Australia 20<sup>th</sup> – 23<sup>rd</sup> September 2009.

**Eijkelkamp BA, Hassan KA, Paulsen IT and Brown MH** MATE pumps in the emerging pathogen *Acinetobacter baumannii*. *ASM 2009*, Perth Convention Exhibition Centre, Western Australia, Australia 6<sup>th</sup> – 10<sup>th</sup> July 2009.

<u>Hassan KA</u>, Lim K, Eijkelkamp BA, Tetu SG, Ren Q, Elbourne LDH, Shaffer B, Loper JE, Brown MH and Paulsen IT High-throughput functional genomics of bacterial efflux proteins. *Gordon Research Conference into Multidrug Efflux Systems*, Hotel Galvez, Galveston, Texas, USA 22<sup>nd</sup> – 27<sup>th</sup> March 2009.

<u>Eijkelkamp BA</u>, Hassan KA, Paulsen IT and Brown MH MATE pumps in the emerging pathogen *Acinetobacter baumannii*. *Gordon Research Conference into Multidrug Efflux Systems*, Hotel Galvez, Galveston, Texas, USA 22<sup>nd</sup> – 27<sup>th</sup> March 2009.

The presenting author has been underlined.